Last updated: August 27, 2026
ESKATA, Aclaris Therapeutics’ hydrogen peroxide 40% topical solution for raised seborrheic keratoses, failed commercially despite FDA approval and a large potential patient population. The product entered a fragmented, largely cash-pay dermatology market with limited reimbursement, office-application requirements, procedural competition and modest repeat-treatment demand. Aclaris discontinued commercial operations after sales failed to support the product’s cost structure.
The central investment conclusion is that ESKATA’s market failure was commercial rather than primarily regulatory. Its active ingredient had low intrinsic exclusivity value, while the product’s formulation, application method and clinical positioning did not create enough pricing power or physician adoption.
What was ESKATA and what did the FDA approve?
ESKATA was a 40% hydrogen peroxide topical solution approved by the U.S. Food and Drug Administration in December 2017 for the topical treatment of raised seborrheic keratoses in adults. The product was developed and commercialized by Aclaris Therapeutics under the brand name ESKATA. [1]
FDA regulatory status
| Item |
ESKATA status |
| Active ingredient |
Hydrogen peroxide |
| Strength |
40% topical solution |
| Indication |
Raised seborrheic keratoses in adults |
| FDA pathway |
505(b)(2)-type regulatory strategy |
| Approval date |
December 2017 |
| Dosage form |
Physician-applied topical solution |
| Administration |
Applied in a medical office, generally over multiple sessions |
| Regulatory category |
Small-molecule dermatology product |
| Current commercial status |
Commercially discontinued |
| Biosimilar exposure |
None |
The approval was narrow. ESKATA was not approved for all seborrheic keratoses, flat lesions or cosmetic skin conditions. The label required health-care professional administration and included warnings involving ocular exposure, irritation, erythema, edema, crusting, pigment changes and scarring-related events. [1]
How large was the ESKATA market opportunity?
The addressable population was large, but the monetizable market was much smaller. Seborrheic keratoses are common benign lesions, particularly among older adults. The commercial opportunity depended on patients paying for treatment, physicians adopting a new office procedure and the product producing an acceptable cosmetic outcome.
ESKATA competed with:
- Cryotherapy using liquid nitrogen.
- Curettage and electrodessication.
- Shave removal.
- Laser and other energy-based procedures.
- Observation, because seborrheic keratoses are generally benign.
- Unapproved or compounded topical preparations.
Why the apparent market size did not translate into revenue
The product had four structural constraints.
First, seborrheic keratosis treatment is frequently elective. Patients and physicians could defer treatment without a medical penalty.
Second, many procedures were performed under fee-for-service dermatology economics. Physicians already had familiar, fast procedures such as cryotherapy and curettage. ESKATA required product training, patient selection, lesion preparation and post-treatment management.
Third, reimbursement was limited. Treatment was often cosmetic or considered nonessential, shifting payment to patients. The product therefore faced price sensitivity even though the disease population was large.
Fourth, treatment demand was episodic. A patient might have multiple lesions at presentation, but treatment did not necessarily produce recurring pharmaceutical demand comparable to chronic dermatology products.
What was ESKATA’s commercial launch strategy?
Aclaris launched ESKATA in early 2018 through a dedicated dermatology sales infrastructure. The company positioned it as an in-office pharmaceutical alternative to destructive procedures. The commercial strategy depended on selling directly to dermatologists and encouraging practices to charge patients for treatment sessions.
That model imposed high fixed costs before demand was proven. Aclaris had to support sales representatives, physician education, sampling, inventory, distribution, training and patient marketing. The economics were difficult because the product did not generate chronic refills and because physicians could use lower-cost procedural alternatives.
ESKATA pricing and practice economics
Publicly reported treatment prices varied by practice, lesion count and geographic market. ESKATA was commonly discussed as a cash-pay treatment with per-session costs that could reach several hundred dollars or more. Product acquisition cost was only one component of the patient’s bill. Physician time, lesion preparation, application and follow-up affected the total treatment price.
The resulting value proposition was sensitive to:
- Number of lesions treated per visit.
- Probability of complete clearance.
- Adverse skin reactions.
- Number of treatment sessions.
- Patient willingness to pay.
- Comparison with low-cost cryotherapy.
The need for multiple applications or visits reduced the product’s convenience advantage. A product intended to replace a familiar procedure had to offer a clear improvement in outcomes, speed, tolerability or economics. ESKATA did not establish that advantage at scale.
What was ESKATA’s financial trajectory?
Aclaris reported commercial revenue from ESKATA after launch, but sales were insufficient to support the product’s commercial infrastructure. Revenue declined sharply after the initial launch period, and the company moved to discontinue the product and reduce its commercial operations.
Financial timeline
| Period |
Commercial development |
Financial implication |
| December 2017 |
FDA approval |
Regulatory risk reduced; launch investment began |
| Early 2018 |
U.S. commercial launch |
Sales force and commercialization costs increased |
| 2018 |
Initial product sales |
Revenue did not validate the full commercial infrastructure |
| January-February 2019 |
Aclaris announced a reduction in ESKATA commercial activities |
Management concluded that product economics were unfavorable |
| 2019 |
Commercial wind-down |
Product revenue declined; restructuring and inventory-related effects became relevant |
| 2020 onward |
ESKATA no longer operated as an active commercial growth product |
No meaningful value remained in the original commercial model |
Aclaris’ securities filings described ESKATA sales as inadequate and stated that the company was discontinuing commercial operations for the product. The company’s broader financial results remained dominated by research and development spending, financing requirements and pipeline restructuring rather than by ESKATA revenue. [2][3]
Revenue quality
ESKATA revenue had weak quality from an investor perspective because it was:
- Concentrated in a single product.
- Dependent on new physician adoption.
- Predominantly associated with elective treatment.
- Exposed to patient cash-pay behavior.
- Unprotected by a durable refill model.
- Insufficient to absorb a national sales organization.
The product’s revenue trajectory therefore had a short launch window and limited visibility. It did not develop into a recurring dermatology franchise.
When did ESKATA lose commercial exclusivity?
ESKATA lost commercial relevance before patent expiry. The product’s market failure occurred while intellectual-property rights and regulatory exclusivity could still have existed.
That distinction matters. Patent life protects the ability to exclude certain competitors, but it does not create demand, reimbursement or physician adoption. ESKATA’s commercial discontinuation demonstrated that the product’s limiting factor was market execution and product-market fit rather than immediate generic substitution.
Regulatory exclusivity
Because hydrogen peroxide was an established active ingredient, ESKATA did not have the economic profile of a conventional new chemical entity with long-duration composition-of-matter protection. Any approval-related exclusivity would have been narrower than a new active pharmaceutical ingredient’s exclusivity.
The relevant commercial barriers were more likely to involve:
- Clinical data supporting the approved indication.
- Product formulation.
- Application method.
- Method-of-use claims.
- Physician familiarity.
- Distribution and training.
FDA approval did not prevent competing procedural treatments, compounded products or alternative topical approaches from addressing the same patient need.
What patents protected ESKATA?
The ESKATA patent estate focused on use and formulation concepts rather than ownership of hydrogen peroxide itself. Aclaris and related entities pursued intellectual property around the use of concentrated hydrogen peroxide for seborrheic keratoses and related dermatologic applications.
Patent strength assessment
| Patent category |
Strategic value |
| Hydrogen peroxide composition |
Weak, because the active ingredient is old and widely known |
| High-concentration topical formulation |
Moderate, depending on claim scope and validity |
| Treatment of seborrheic keratoses |
Potentially meaningful for the approved use |
| Application protocol |
Potentially useful, but easier to design around than composition claims |
| Manufacturing know-how |
Limited to moderate; formulation stability and packaging could matter |
| Commercial barrier |
Low after discontinuation |
A method-of-use patent could have complicated a directly substitutable generic product for the same indication. It would not have blocked cryotherapy, curettage, laser procedures or other non-pharmaceutical treatment methods.
Orange Book status
ESKATA’s Orange Book relevance is limited because the product is no longer an active commercial franchise. Any listed patent would have been relevant to an abbreviated new drug application only if the proposed generic relied on the same listed drug and sought the same type of approval.
The practical value of any Orange Book listing fell after Aclaris discontinued sales. A generic company would still have to establish manufacturing feasibility, clinical substitutability and commercial demand. Patent clearance alone would not make the market attractive.
Were there Paragraph IV challenges to ESKATA?
No major, commercially consequential Paragraph IV challenge became a defining event in ESKATA’s market history.
For a product such as ESKATA, a Paragraph IV filing would have required a generic applicant to challenge relevant listed patents while seeking approval under the abbreviated new drug application pathway. The commercial incentive was limited because:
- The branded market was small.
- Patient demand was elective.
- Physician administration complicated substitution.
- The product required specialized packaging and handling.
- Competing procedures were already established.
- The brand owner had already withdrawn from active commercialization.
The absence of a prominent Paragraph IV litigation battle should not be interpreted as evidence of a strong patent estate. It more likely reflected weak generic-market economics.
What formulation and manufacturing barriers affected ESKATA?
Hydrogen peroxide is chemically reactive and can create stability, compatibility and packaging challenges at high concentrations. A commercial product must control concentration, degradation, container interaction and safe delivery.
Potential technical barriers included:
- Maintaining hydrogen peroxide concentration during shelf life.
- Selecting compatible containers and applicators.
- Preventing leakage or degradation.
- Managing exposure to skin and eyes.
- Delivering a consistent volume to each lesion.
- Supporting physician handling and storage.
- Controlling irritation and post-treatment effects.
These barriers could raise the cost of a generic or compounded substitute. They did not, however, create a durable commercial moat because the underlying active ingredient was inexpensive and the patient need could be addressed procedurally.
Which companies challenged ESKATA commercially?
ESKATA did not face a single dominant branded pharmaceutical rival. Its competitive set was distributed across dermatology practices and procedures.
Main competitors
| Competitor |
Competitive mechanism |
Relative advantage |
| Cryotherapy |
Liquid nitrogen destruction |
Familiar, fast and widely available |
| Curettage |
Mechanical removal |
Established and flexible |
| Electrodessication |
Electrical destruction |
Useful for selected lesions |
| Shave removal |
Minor procedure |
Immediate physical removal |
| Laser procedures |
Energy-based treatment |
Cosmetic positioning in selected practices |
| Compounded topicals |
Lower-cost topical alternatives |
Potential cash-pay price advantage |
| No treatment |
Observation |
No cost or procedural risk |
ESKATA’s challenge was not simply a rival drug with a better patent. It was a market with multiple substitutes and low switching costs for physicians.
What litigation affected ESKATA?
No major patent litigation materially altered ESKATA’s commercial trajectory. The decisive event was Aclaris’ own withdrawal and commercial restructuring rather than an injunction, patent invalidation or settlement with a generic manufacturer.
Settlement agreements and licensing
No high-value licensing transaction or settlement agreement became central to the ESKATA business. Aclaris’ strategic response was to reduce or end commercial investment rather than monetize ESKATA through a major licensing arrangement.
The absence of a substantial licensing exit suggests that potential partners did not view the product’s remaining commercial rights as sufficiently attractive to fund a relaunch at scale.
How did ESKATA compare with competing dermatology products?
ESKATA had a different economic model from chronic dermatology drugs such as topical steroids, retinoids or psoriasis treatments.
| Factor |
ESKATA |
Chronic dermatology product |
| Treatment frequency |
Episodic |
Repeated or continuous |
| Refill potential |
Low |
Higher |
| Reimbursement |
Often limited |
More likely in covered disease states |
| Physician workflow |
In-office application |
Often prescribed for home use |
| Substitution risk |
Procedures and observation |
Other drugs in the same class |
| Revenue visibility |
Low |
Typically higher |
| Patient need |
Often elective |
Frequently medically necessary |
| Sales model |
Procedure-oriented |
Prescription and pharmacy-oriented |
This comparison explains why a large lesion population did not produce a large pharmaceutical market. ESKATA was commercially closer to a dermatology procedure product than to a recurring prescription therapy.
What generic launch risks exist for ESKATA?
Generic launch risk was theoretically present but commercially muted.
A generic entrant could have pursued a 505(j) application if the reference product, formulation and labeling permitted that route. A 505(b)(2) approach could have been considered if the proposed product differed materially from the reference product or required reliance on published data. The practical obstacles included:
- Product discontinuation and limited reference-market activity.
- Difficulty demonstrating a viable sales channel.
- Limited physician demand.
- Lack of pharmacy substitution because treatment occurred in-office.
- Potential formulation-stability requirements.
- Competition from inexpensive procedural care.
- Limited opportunity for recurring revenue.
A generic launch would likely have targeted a niche office-use market rather than a broad retail prescription market.
Does ESKATA face biosimilar risk?
No. ESKATA is a small-molecule topical product, not a biologic. Biosimilar regulations do not apply. Competitive entry would involve a generic, a 505(b)(2) product, a compounded formulation or a non-drug procedure.
What is the geographic coverage of ESKATA?
ESKATA’s principal commercial opportunity was the United States, where Aclaris held FDA approval and built its launch infrastructure. The company did not establish ESKATA as a significant global dermatology product.
The limited geographic footprint increased dependence on U.S. physician adoption and cash-pay demand. It also reduced the ability to offset weak U.S. performance with international licensing or regional commercialization deals.
What was the ultimate value of the ESKATA franchise?
The ESKATA franchise had residual intellectual-property and technical value but little continuing commercial value after discontinuation.
Value assessment
| Asset |
Residual value |
| FDA approval |
Limited after commercial withdrawal |
| Brand recognition |
Low |
| Active ingredient |
Low standalone value |
| Formulation know-how |
Possible niche value |
| Method-of-use patents |
Potential defensive value |
| Manufacturing process |
Moderate only if stability and packaging are difficult |
| Commercial platform |
Not durable |
| Licensing potential |
Limited |
| Reimbursement position |
Weak |
The product’s experience also affected Aclaris’ corporate trajectory. The company shifted away from a commercial dermatology model centered on ESKATA and toward pipeline development and licensing-oriented activities. [2][3]
Key Takeaways
- ESKATA was FDA-approved in December 2017 for raised seborrheic keratoses in adults.
- Its commercial market was constrained by cash-pay treatment, limited reimbursement and low repeat-use potential.
- Cryotherapy, curettage and other office procedures were the main competitive threats.
- Aclaris discontinued commercial operations after sales failed to support the product infrastructure.
- ESKATA’s financial trajectory was a short launch followed by rapid commercial contraction.
- The patent estate focused on formulation, treatment methods and application concepts rather than a new active ingredient.
- No major Paragraph IV challenge, patent trial or settlement drove the product’s decline.
- ESKATA has no biosimilar risk because it is a small-molecule topical drug.
- Generic risk is technically possible but commercially limited by low demand and in-office administration.
- The principal failure was product-market fit, not an immediate loss of patent protection.
FAQs
Was ESKATA removed from the market because it was unsafe?
Aclaris’ commercial withdrawal was driven by insufficient commercial performance and unfavorable product economics. FDA labeling identified expected topical and ocular risks but did not establish that a safety event caused the commercial discontinuation. [1][2]
Can a dermatologist still prescribe ESKATA?
ESKATA is not an active commercial product from Aclaris. Availability through standard commercial distribution is therefore limited, and the FDA’s discontinued-drug records should be distinguished from a safety-based withdrawal. [4]
Could hydrogen peroxide 40% be compounded for seborrheic keratoses?
Compounded preparations would raise separate quality, stability, labeling and regulatory questions. They would not automatically be therapeutically or legally equivalent to the FDA-approved ESKATA product.
Why did ESKATA need physician administration?
The product had to be applied directly to individual lesions, with precautions to avoid ocular exposure and manage local skin reactions. The office-based process also affected treatment economics and limited ordinary pharmacy substitution. [1]
Was ESKATA a blockbuster opportunity?
No. The patient population was large, but the addressable pharmaceutical market was constrained by elective treatment, low recurrence, procedural substitutes and weak reimbursement. The launch did not achieve the revenue scale required for a durable standalone franchise.
References
-
U.S. Food and Drug Administration. (2017). ESKATA (hydrogen peroxide) topical solution, 40%: Prescribing information. FDA.
-
Aclaris Therapeutics, Inc. (2019). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K for fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission.
-
Aclaris Therapeutics, Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K for fiscal year ended December 31, 2019. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (n.d.). Discontinued drugs. FDA.
